Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.59 |
| ▸ | GRIN1 | Q05586 | 15/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 15/20 | 0.59 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19219284 | 0.86 | RXRA (0.58) | RXRAGRIN1GRIN2BP2RX7CA12 | |
| SCHEMBL19219279 | 0.83 | RXRA (0.64) | RXRAGRIN1GRIN2BP2RX7CA2 | |
| SCHEMBL19211332 | 0.81 | RXRA (0.86) | RXRAGRIN1GRIN2B | |
| SCHEMBL19219280 | 0.81 | GRIN1 (0.60) | RXRAGRIN1GRIN2BP2RX7CA12 | |
| SCHEMBL19219271 | 0.79 | RXRA (0.66) | RXRAGRIN1GRIN2BP2RX7NPC1 | |
| SCHEMBL19219272 | 0.79 | RXRA (0.68) | RXRAGRIN1GRIN2BP2RX7NPC1 | |
| SCHEMBL19219274 | 0.76 | RXRA (0.62) | RXRAGRIN1GRIN2BP2RX7NPC1 | |
| SCHEMBL19219276 | 0.75 | RXRA (0.60) | RXRAGRIN1GRIN2BP2RX7NPC1 | |
| SCHEMBL19219342 | 0.75 | RXRA (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL19211374 | 0.74 | RXRA (0.82) | RXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | RXRA 2100/4885GRIN1 3/4885GRIN2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.